Company intelligence / Profile preview

Vivaldi Biosciences

Fort Collins, Colorado, USAvivaldibiosciences.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Vivaldi Biosciences develops deltaFLU, a universal intranasal influenza vaccine based on deletion of the NS1 gene from the influenza virus. This approach yields a replication-deficient, live attenuated vaccine that induces strong interferon responses and broad cross-protection against diverse strains. Four completed clinical studies show deltaFLU to be safe and immunogenic in adults. Nonclinical data demonstrate superior protection versus licensed vaccines against mismatched strains. The company has also established a rapid, high-yield cell-based manufacturing process using Vero cells.

Therapeutic areas: Infectious Diseases
Modalities: Live attenuated vaccineProphylactic vaccineFusion proteinMultivalent vaccineVaccine
Industry: Biotech

Drug pipeline

4 assets

DeltaFLU

3 more assets in the full pipeline.

Beyond the preview

Go deeper on Vivaldi Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivaldi Biosciences.